Camouflage! An Innovative but Crappy Use for SBIR Reauthorization

.
Just when you thought you’d seen everything. The lengths our limping quackers will go to make their Lame Duck session productive is absolutely stunning. But you’ve got to give them credit for innovation.

I use GovTrack to keep me informed of activities on bills in process with regard to SBIR. One I was tracking was H.R.2965 – the House version of SBIR Reauthorization. When it showed action last week, I eagerly went to see what was up. The Title hadn’t changed. But the bill’s Text had changed – to the repeal of “Don’t Ask, Don’t Tell”! Huh?

I made some quick inquiries, and was given a quick brief on the tactic being employed – using H.R.2965 as camouflage because it was far enough along in the process to avoid having to be further discussed by either chamber and could be immediately voted upon. The title of the bill wasn’t changed, just the text. We know our legislators don’t read the bills they vote on. It was to be a sneak attack. And, it worked.

I was asked to not rattle the cage yet, as some behind-the-scenes action was simultaneously happening with the Senate’s version (S.1233) along with discussions with BIO that just might get things settled, and we were to “stay out of the way”. OK. I’m a good soldier. I put the “pen” down and waited.

Last night Rick Shindell published an SBIR Insider about this monkey business. As they used to say: READ ALL ABOUT IT: SBIR Insider of December 19, 2010. The cat’s out of the bag, so I got out the pen.

I know this is how things get done in Washington, but I don’t have to like it. Resorting to camouflage and subterfuge to sneak things by is just wrong. I don’t care what the issue is. Not that this is anything new to us -- the NIH's sneaky ARRA SBIR exclusion is a case in point.

Frankly, I’m fed up with political posturing, pouting, pontificating, and prevaricating. No one tells the truth about anything. They tell the politically expedient story and use perception management to make it seem like the truth.

Yes, I have mixed emotions. On the one hand I’m delighted to see the guts ripped out of H.R.2965. It was a bad bill. But I know one thing for sure. The deliberate use of SBIR’s name for unrelated political expediency was distasteful. The crappy tactic of not changing the title when the bill has been totally changed should be illegal, but the Congress makes its own rules, and holds itself to a different standard, both legal and ethical.

I guess I wouldn’t make a good politician. I know how to play the SBIR game, and I think I’ve played it well. But this game is another story. To have used a small business bill in this way is flat out dishonest. No one asked me, but I’m telling!

Now what? Will this be another instance of Huggem-Muggem? Now that they've used us for their own nefarious purposes, will SBIR be summarily cast aside and handed off to the next Congress to start over?

Or will the Senate, the House, BIO, NVCA, SBTC, and the NSBA all agree to do what's best for small business and emerge yet this session with an SBIR Reauthorization compromise we can all live with?

Will the egos of our legislators, especially those in the House, be soothed to where they’ll act responsibly instead of selfishly? Will Nydia put her purse away? Will pigs fly?

Don't let my disgust with the process and those who would use it for their own selfish purposes make you think I've given up. I'm basically an optimist. And a realist.

Maybe pigs really will fly. Stay tuned.
.

BIO Endorses Senate SBIR Reauthorization Bill -- Co-Sponsors Sought

.
They said it couldn't be done! Impossible. Never happen. But it did!

The SBIR Advocacy and the Biotechnology Industry Organization (BIO) agree on an SBIR Reauthorization bill!

In a unanimous endorsement, the Senate Small Business and Entrepreneurship (SBE) Committee passed S.1233 up to the full Senate for consideration yesterday.

BIO immediately endorsed it too, joining the SBTC in recommending its passage!

In an article that appeared on GenomeWeb.com moments after the SBE Committee's action was announced, Jim Greenwood, BIO's CEO, is cited as having lauded the Bill! That's not to say that BIO won't promote amendments, but lauding is lauding! Guess we'll just have to wait and see what ensues in the full Senate debate.

Greenwood is quoted as urging Congress to reauthorize the SBIR program "as soon as possible in a way that provides a level playing field." Oh, really? Sort of ironic, eh what! A tip of my hat to you, JG! I appreciate chutzpah, being somewhat unabashed myself!

And, way to go, SBE Committee! And especially, thank you Senators Landrieu and Snowe for leading the way on this.

OK, let's get S.1233 Co-Sponsors lined up! If we can show overwhelming bi-partisan support for this Bill, there will be intense pressure put on the House to conform to it.

There's a Call to Action for enlisting S.1233 Co-Sponsors on the www.SBIRreauthorization.com website.

You'll find a model letter, links to Senatorial contact information, and a copy of the GenomeWeb article to attach.

Any questions? OK, team, let's get busy! Everybody's in the game! Fax letters, make calls.

We can do this. Nothing is impossible. It just takes a little longer!
.